BiondVax receives second EUR6M tranche disbursement from the European Investment Bank (EIB)
(WorldNews Asia)

NESS ZIONA, Israel, August 14, 2018 - BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), developer of M-001, a clinical phase 3 Universal Influenza Vaccine candidate, announced today the receipt of a EUR6 million disbursement from the European Investment Bank (EIB). These funds are the second tranche of the previously announced EUR20 million co-financing agreement signed in June 2017. The first tranche of EUR6 million was received by BiondVax in June 2018. Dr. Ron Babecoff, BiondVax`s CEO, stated, `I am grateful to the EIB for their ongoing support, which has helped us reach our targets including the recent launch of our pivotal Phase 3 trial and the construction of a new mid-size commercial...